28 / 56
HIPERTENSION / 2013 / VOL. 18
26
Bibliografía
1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
2. Alderman MH, Budner N, Cohen H, Lamport B, Ooi WL. Prevalence of drug resistant hypertension. Hypertension 1988;11:II71-5.
3. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991;151:1786-92.
4. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-80.
5. Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association
Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
6. Viera AJ, Hinderliter AL. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician 2009;79:863-9.
7. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:239-44.
8. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:619-26.
9. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
10. Pitt B, Zannad F, Remme WJ, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine
1999;341:709-17.
11. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens
2002;15:333-9.
12. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30.
13. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J
Hypertens 2006;19:750-5.
14. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
15. Segura J, Cerezo C, Garcia-Donaire JA, et al. Validation of a therapeutic scheme for the treatment of resistant hypertension. Journal of the American Society of
Hypertension : JASH 2011;5:498-504.
16. Václavík J, Sedlák R, Plachý M, et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind,
Placebo-Controlled Trial. Hypertension 2011;57:1069-75.
17. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-5.
18. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004;22:863-9.
19. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-
6.
20. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.
21. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004;43:518-24.
22. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension. Hypertension 2010;55:147-52.
23. Clark D, 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012;28:318-25.
24. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature reviews Nephrology 2013;9:459-69.
25. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.
26. Dickson GM. Menopause management: how you can do better. The Journal of family practice 2012;61:138-45.
27. Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone
blockade in chronic kidney disease. Hypertension 2009;53:754-60.
28. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92.
29. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30:418-24.
30. Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern
Med 2009;169:1587-94.
31. Sica DA. The risks and benefits of therapy with aldosterone receptor antagonist therapy. Current drug safety 2007;2:71-7.
Conclusiones
La utilización de los bloqueadores del receptor mineralocorticoide como espironolactona en
sujetos con HTA resistente produce una importante reducción adicional de la PA, independiente si
presenten o no un hiperaldosteronismo primario. Por ello debe estimularse su uso en esta situación,
respetando las precauciones y recordando que la hiperkalemia es más frecuente en sujetos con
insuficiencia renal, DM, ancianos o en aquellos con bloqueo del SRA o ingesta de AINEs
(31)
.